It was a shocking summer for Germany’s GPC Biotech AG . The biotech’s stock lost more than 70% of its value in late July after an FDA advisory committee unanimously recommended that FDA delay considering prostate cancer candidate satraplatin for approval until overall survival data from the group’s 950-patient SPARC (satraplatin and prednisone against refractory cancer) trial is available.
As if that wasn’t enough, GPC was then slapped with a class action lawsuit from shareholders alleging that it lied...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?